[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dong-A ST Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":236},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,64,86,108,128,149,167,190,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":37,"locationsCount":40},"100643815","phase-1-a-study-to-exploratively-evaluate-the-safety-tolerability-and-pharmacokinetics-of-da-5223-compared-with-da-5223-r-in-healthy-adult-subjects-100643815",false,"NCT07633691","A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, Two-Cohort, Two-Period, Crossover Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","Inclusion Criteria:\n\n* Adult male or female, 19 years to 55 years\n* Male weighing 50 kg or more, female weighing 45 kg or more with a body mass index (BMI) of 18.0 kg\u002Fm2 to 30.0 kg\u002Fm2\n* The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate\n\nExclusion Criteria:\n\n* The subjects with acute illness\n* The subjects with a history of gastrointestinal disease or surgery that may affect the absorption of Investigational Product\n* The subjects hypersensitive to any of the Investigational Product components or other drug components\n* The subjects who have continuously consumed excessive smoking or alcohol within 1 months of screening, or who cannot stop smoking, caffeine, or alcohol intake during hospitalization\n* The subjects who are pregnant or lactating",true,"ALL","19 Years","55 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study will exploratively evaluate the safety, tolerability and pharmacokinetics of DA-5223 compared with DA-5223-R in healthy adult subjects",[28],"Healthy Adult","RECRUITING","2026-06-04",{"date":32,"type":33},"2026-06-08","ACTUAL",{"date":35,"type":22},"2026-06",{"date":35,"type":22},{"name":38,"class":39},"Dong-A ST Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100629952","phase-1-a-first-in-human-phase-iiia-study-to-evaluate-da-3501-in-patients-with-advanced-gastric-or-gastro-esophageal-junction-adenocarcinoma-and-pancreatic-ductal-adenocarcinoma-100629952","NCT07481357","A First-In-Human Phase I\u002FIIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","A First-In-Human Phase I\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n1. Patients aged ≥ 19 years\n2. Histologically or cytologically documented advanced CLDN18.2+ GC\u002FGEJ adenocarcinoma or advanced CLDN18.2+ PDAC\n3. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)\n4. Life expectancy ≥12 weeks as judged by the Investigator\n\nExclusion Criteria:\n\n1. Cardiac abnormalities\n2. Gastrointestinal abnormalities\n3. Active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), known hepatitis C virus (HCV), known human immunodeficiency virus (HIV).\n4. Active systemic infection requiring IV antibiotics therapy.",{"count":49,"type":22},51,[25],"The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC\u002FGEJ and advanced CLDN18.2+ PDAC.\n\nParticipants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.",[53,54,55],"Gastric (Stomach) Cancer","GastroEsophageal Cancer","Pancreatic Ductal Adenocarcinoma (mPDAC)","2026-05-18",{"date":58,"type":33},"2026-05-20",{"date":56,"type":33},{"date":61,"type":22},"2029-02",{"name":38,"class":39},3,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100632435","phase-1-a-study-to-evaluate-the-bioequivalence-of-da-5230-compared-to-da-5230-r-100632435","NCT07513649","A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy participants aged 19 to 55 years at the time of screening visit\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n\nExclusion Criteria:\n\n* Participants who have received an investigational product in another clinical trial or a bioequivalence study within 6 months prior to the first dosing\n* Participants deemed unsuitable for participation in this clinical trial by the investigator",{"count":72,"type":22},60,[25],"A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R",[76],"Healthy Adult Participants","NOT_YET_RECRUITING","2026-03-31",{"date":80,"type":33},"2026-04-07",{"date":82,"type":22},"2026-04",{"date":84,"type":22},"2026-05",{"name":38,"class":39},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100611350","phase-2-clinical-trial-to-evaluate-the-efficacy-and-safety-of-da-2811-when-added-to-ongoing-bt-1-and-bt-2-combination-therapy-in-patients-with-type-2-diabetes-who-have-inadequate-glycemic-control-100611350","NCT07239440","Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","Inclusion Criteria:\n\n1. Patients with type II diabetes mellitus aged 19 years or older\n2. Patients with fasting plasma glucose≤270mg\u002FdL at the screening visit\n3. Patients with 18.5kg\u002Fm\\^2≤BMI≤40kg\u002Fm\\^2 at the screening visit\n4. Patients who have signed an informed consent themselves after receiving detailed explanation about the clinical study\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis\n2. Patients with a medical history of New York Heart Association(NYHA) class III\\~IV heart failure or with congestive heart failure, acute and unstable heart failure\n3. Patients with severe infectious disease or severe traumatic systemic disorders\n4. Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction and other hypoxemia\n5. Patients with galactose intolerance, lapp lactase deficiency, glucosegalactose malabsorption",{"count":94,"type":22},288,[96],"PHASE2","This study is a multicenter, double-blind, active-controlled, randomized, parallel clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing BT-1 and BT-2 combination therapy in patients with type 2 diabetes who have inadequate glycemic control",[99],"Diabete Mellitus","2025-11-16",{"date":102,"type":33},"2025-11-20",{"date":104,"type":22},"2025-11",{"date":106,"type":22},"2027-06",{"name":38,"class":39},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100610588","phase-4-clinical-trial-to-evaluate-the-efficacy-and-safety-of-da-5218-in-patients-with-type-2-diabetes-100610588","NCT07229534","Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes","A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","Inclusion Criteria:\n\n* 7.0%≤HbA1c≤10.5% and fasting glucose≤270mg\u002FdL\n* Treated with 1,000mg\u002Fday dose of metformin for at least 8 weeks\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus\n* eGFR\\\u003C45mL\u002Fmin\u002F1.73m2\n* ALT and AST 3 times or higher than upper normal range\n* Determined by investigator as unfit to participate in a clinical trial due to other reasons",{"count":116,"type":22},238,[118],"PHASE4","This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin",[99],"2025-11-13",{"date":123,"type":33},"2025-11-17",{"date":104,"type":22},{"date":126,"type":22},"2027-11",{"name":38,"class":39},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":40},"100592419","phase-1-clinical-trial-of-comparing-da-5222-single-administration-and-co-administration-of-da-5222-r1-da-5222-r2-and-da-5222-r3-in-healthy-adult-subjects-100592419","NCT06993181","Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted\n* Subjects with allergy or drug hypersensitivity",{"count":136,"type":22},48,[25],"This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects",[140],"Healthy","2025-06-03",{"date":143,"type":33},"2025-06-06",{"date":145,"type":22},"2025-06",{"date":147,"type":22},"2025-07",{"name":38,"class":39},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":166,"locationsCount":40},"100592418","phase-1-to-evaluate-effect-of-food-of-da-5222-in-healthy-adult-subjects-100592418","NCT06993168","To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of DA-5222 in Healthy Adult Subjects",{"count":156,"type":22},32,[25],"This study is to evaluate the effect of food on pharmacokinetics of DA-5222 in healthy adult subjects",[140],"2025-05-19",{"date":162,"type":33},"2025-05-28",{"date":164,"type":22},"2025-05-21",{"date":147,"type":22},{"name":38,"class":39},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100538654","phase-1-clinical-trial-to-investigate-safety-tolerability-pharmacokinetics-pharmacodynamics-and-efficacy-of-da-4505-as-a-single-agent-and-in-combination-with-pembrolizumab-in-adult-patients-with-locally-advanced-or-metastatic-solid-tumors-100538654","NCT06293651","Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","an Open-Label, Phase 1\u002F2a, First-in-Human Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Aged 18 and older.\n2. Capable of giving signed informed consent.\n3. Diagnosed with particular disease characteristics.\n4. Expected survival ≥ 3 months.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n6. A female patient is eligible to participate if she is not pregnant or breastfeeding.\n7. A male patient is eligible to participate if he agrees to remain abstinent or use a male condom when having sexual intercourse with a WOCBP, or if he has had a bilateral vasectomy.\n8. Have measurable disease by revised RECIST v1.1 criteria.\n\nExclusion Criteria:\n\n1. Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.\n2. Current enrollment or past participation in another clinical trial.\n3. Unresolved adverse reactions (except alopecia) from previous cancer-directed therapy.\n4. Use of cancer-directed therapies, including chimeric antigen receptor T cell therapy.\n5. Autologous transplantation within 60 days.\n6. Prior allogeneic transplantation.\n7. Major surgery within 30 days, or unresolved complications after a major or minor surgery.\n8. History of or currently active cardiovascular disease.\n9. Clinically significant respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders.\n10. History of other malignancy.","18 Years",{"count":176,"type":22},125,[25,96],"This study is an Open-Label, Phase 1\u002F2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.",[180],"Locally Advanced or Metastatic Solid Tumors","2025-02-10",{"date":183,"type":33},"2025-02-12",{"date":185,"type":33},"2024-04-18",{"date":187,"type":22},"2029-10",{"name":38,"class":39},2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":40},"100563493","phase-1-pharmacokinetics-and-safety-profiles-after-administration-of-da-522101-and-co-administration-of-522101-r1-and-da-522101-r2-in-healthy-adult-volunteers-100563493","NCT06616883","Pharmacokinetics and Safety Profiles After Administration of DA-5221_01 and Co-administration of 5221_01-R1 and DA-5221_01-R2 in Healthy Adult Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Study to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Single Administration of DA-5221_01 and Concomitant Administration of DA-5221_01-R1 and DA-5221_01-R2 Under Fasting Conditions in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy volunteers\n* BMI between 18 and 30 kg\u002Fm2\n* Body weight: Male≥50kg, Female≥45kg\n* Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study\n\nExclusion Criteria:\n\n* Subjects with clinically significant medical history\n* Subjects with history of drug abuse or addicted",{"count":198,"type":22},44,[25],"Pharmacokinetics and Safety Profiles After Administration of DA-5221\\_01 and Co-administration of 5221\\_01-R1 and DA-5221\\_01-R2 in Healthy Adult Volunteers",[140],"2024-09-25",{"date":204,"type":33},"2024-09-27",{"date":206,"type":22},"2024-09-30",{"date":208,"type":22},"2024-11-18",{"name":38,"class":39},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":217,"maxAge":4,"enrollmentInfo":218,"targetDuration":220,"studyType":221,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":40},"100423808","long-term-safety-and-effectiveness-of-growtropin-ii-treatment-in-children-with-short-stature-100423808","NCT04798690","Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Open, Multi-center, Non-interventional, Prospective\u002F Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Inclusion Criteria:\n\n* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)\n* Children who has official height record at least 6 months prior\n\nExclusion Criteria:\n\n* Children with Epiphyseal closure","2 Years",{"count":219,"type":22},2500,"10 Years","OBSERVATIONAL","This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.",[224,225,226,227],"Growth Hormone Deficiency","Idiopathic Short Stature","Turner Syndrome","Small for Gestational Age","2023-04-11",{"date":230,"type":33},"2023-04-12",{"date":232,"type":33},"2021-02-08",{"date":234,"type":22},"2031-12",{"name":38,"class":39},""]